Alignment Healthcare (NASDAQ:ALHC) Insider Sells $214,080.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Andreas Wagner sold 12,000 shares of the stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total value of $214,080.00. Following the completion of the sale, the insider owned 160,230 shares of the company’s stock, valued at approximately $2,858,503.20. This trade represents a 6.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Alignment Healthcare Stock Performance

Alignment Healthcare stock opened at $17.34 on Friday. The firm has a market capitalization of $3.54 billion, a PE ratio of -1,732.27, a price-to-earnings-growth ratio of 2.54 and a beta of 1.18. Alignment Healthcare, Inc. has a one year low of $11.63 and a one year high of $23.87. The stock’s 50 day moving average price is $20.44 and its 200 day moving average price is $18.80. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.10. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. Alignment Healthcare’s revenue for the quarter was up 44.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.16) earnings per share. As a group, sell-side analysts expect that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

More Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Strong fundamentals — Alignment reported Q4 revenue of ~$1.01B and an EPS beat (‑$0.05 vs. consensus ‑$0.15) with revenue up ~44% YoY, which supports longer‑term growth expectations. Earnings Summary
• Positive Sentiment: Analyst bullishness — Multiple brokerages have raised price targets and maintain Buy/Overweight views (e.g., TD Cowen, JPMorgan, KeyCorp, Robert W. Baird), leaving a consensus analyst stance that is constructive for the stock. Analyst Coverage
• Neutral Sentiment: Short‑interest data published for March appears erroneous (shows 0 shares / NaN changes). Do not treat those figures as evidence of new short pressure until exchanges correct the data.
• Neutral Sentiment: High institutional ownership (~86%) can mute volatility from retail flows but also means institutional positioning matters for future moves; a Zacks comparison piece contrasts ALHC with peers for valuation context. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Secondary offering announced by a major shareholder — the planned secondary raises potential near‑term selling supply and is a clear negative for price action until the offering size and timing are known. Alignment Healthcare announces secondary offering by major shareholder
• Negative Sentiment: Clustered insider selling — several senior executives reported sales on Mar 18–19 (CEO John E. Kao: 73,046 shares; President Dawn Maroney: 36,749; COO Sebastian Burzacchi: 15,361; plus multiple other officers, and Robert Scavo sold 11,285). These simultaneous disposals (~tens of thousands of shares each at ~$17.84) create headline risk and likely contributed to today’s negative sentiment. Representative SEC filings: Kao — Kao SEC Filing, Scavo — Scavo SEC Filing

Institutional Trading of Alignment Healthcare

Institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP boosted its stake in Alignment Healthcare by 8.9% during the 4th quarter. Allworth Financial LP now owns 6,917 shares of the company’s stock valued at $137,000 after acquiring an additional 566 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of Alignment Healthcare by 6.0% in the 4th quarter. State of Alaska Department of Revenue now owns 11,296 shares of the company’s stock worth $223,000 after purchasing an additional 636 shares during the last quarter. Integrated Wealth Concepts LLC increased its position in shares of Alignment Healthcare by 6.3% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 11,230 shares of the company’s stock worth $196,000 after purchasing an additional 665 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of Alignment Healthcare by 87.7% in the 4th quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after purchasing an additional 773 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its stake in shares of Alignment Healthcare by 2.3% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,752 shares of the company’s stock valued at $659,000 after purchasing an additional 844 shares in the last quarter. 86.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ALHC has been the topic of several analyst reports. UBS Group lifted their price target on shares of Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 14th. Robert W. Baird set a $28.00 price objective on shares of Alignment Healthcare in a research report on Friday, January 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. Wall Street Zen lowered Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, TD Cowen boosted their price target on Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Alignment Healthcare currently has an average rating of “Moderate Buy” and a consensus target price of $24.56.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.